Clinical Trial

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine (PCV) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative breast cancer undergoing neoadjuvant chemoimmunotherapy.
Protocol Amendment History 5 changes
critical Primary endpoint(s) modified 2026-06-16
notable Primary completion pushed: 2030-04-08 -> 2030-05-31 2026-06-16
minor Completion pushed: 2035-03-09 -> 2035-04-30 2026-06-16
notable Primary completion pushed: 2030-01-08 -> 2030-04-08 2026-05-08
minor Completion pushed: 2034-12-09 -> 2035-03-09 2026-05-08
Trial Details
NCT Number NCT07300475
Lead Sponsor Washington University School of Medicine
Conditions Triple Negative Breast Cancer
Enrollment 30 participants
Start Date 2026-08-01
Primary Completion 2030-05-31 (estimated)
Study Completion 2035-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-15